Genomics analytics platform developer Sophia Genetics has gone public ten years after it was co-founded by researchers from EMBL, Stanford and University of Geneva

Dog DNA test developer Embark Veterinary raised the capital in a round led by SoftBank Vision Fund 2 at a $700m post-money valuation.

Co-founder and CEO Kelli Luginbuhl talks to GUV about how the Duke spinout re-imagines the manufacturing of complex biologics.

The heath and nutrition product manufacturer's Otsuka Nutraceutical Emerging Ventures vehicle will target early-stage investments in North America.

AGC, JSR Life Sciences and Merck & Co all scored exits as the synthetic biology technology developer floated on Nasdaq, whose valuation reportedly stands at nearly $2bn.

Takeda has returned to back the cancer therapeutics developer’s series D round after committing $120m in equity and milestone financing just over 18 months ago.

Branding services provider Tailor Brands raised $50m in a GoDaddy-led series C round while Orix is set to exit hiring software developer PandoLogic in a $150m acquisition.

UC Berkeley’s cancer therapy developer priced a $304m initial public offering at the top of its range.

Yale University is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.

The Corteva, Novartis, AbbVie and Heritage Medical Systems-backed cancer therapy developer priced a $304m initial public offering at the top of its range.